GS-441524 is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective in vitro against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats.
If a cat’s immune system is healthy and mature, the defence provided by the white blood cells should help to combat any infection or virus. Cats who develop FIP, however, have an immune defect or deficiency which means that the virus is replicated rather than fought by the white blood cells, thus spreading it throughout the cat’s body instead. Felines with no resistance to the virus develop wet FIP, while those with a partial immune response experience dry FIP.
The nucleoside analog GS441524 attempts to stop the replication of the virus by acting as an alternative substrate and RNA-chain terminator of viral RNA dependent RNA polymerase. This means that GS441524 interjects itself into the chain reaction and halts the process, subsequently preventing the virus from infecting other cells. This subsequently enables the cat’s immune system to defend against the virus more effectively.
Packing: 1 box * 10 vials
Recommended treatment: 12 weeks.
Recommended dosage:*DOSAGE IS BASED ON THE WEIGHT AND SYMPTOMS*
Ascites / pleural effusion: 0.5mL/kg * body weight kg + 0.1 residue
FIP(Wet):0.4mL/kg * body weight kg + 0.1 residue
FIP(Dry): 0.6mL/kg * body weight kg + 0.1 residue
Eye / nerve entry: 0.7mL/kg * body weight kg + 0.1 residue
Recurrence: 0.9 mL/ kg * body weight kg + 0.1 residue
